M2Gen® Appoints New Vice President of Strategy and Business Development

May 11, 2015

TAMPA, Fla. – Naveen Kumar has been named Vice President of Strategy and Business Development at M2Gen®, Moffitt Cancer Center’s wholly owned, for-profit, informatics solution subsidiary advancing personalized medicine by using high quality tissue, clinical data and molecular technology to accelerate the discovery and delivery of personalized medicine. In his new role, Naveen will oversee the development and execution of M2Gen’s commercial activities and corporate growth strategy. 

Kumar joined M2Gen in 2012 and has served as the executive director of corporate development, and prior worked in a business consulting role with the Moffitt strategic planning team. “Naveen’s contributions to the growth of M2Gen ranging from the development of our collaborations with biopharmaceutical companies to the formation of the Oncology Information Exchange Network (ORIEN) have been invaluable,” said Bill Dalton, Ph.D., M.D., CEO of M2Gen. 

“M2Gen is at an exciting point in its growth,” Kumar said. “I am honored to be part of that growth, and thrilled to be working with such a passionate team here to accelerate the discovery and development of personalized medicines.”    

Before joining Moffitt and M2Gen, Kumar worked in the finance and consulting roles where he worked closely with life sciences companies to develop and execute on key financial and strategic initiatives. Naveen holds a B.A, with Honors, from New York University and a M.Sc. in Finance and Economics from the London School of Economics.

About M2Gen®
M2Gen® is Moffitt Cancer Center’s wholly owned, for-profit, informatics solution subsidiary advancing personalized medicine by using high quality tissue, clinical data and molecular technology to accelerate the discovery and delivery of personalized medicine.  Using a rapid learning approach, the goal of M2Gen is to accelerate the science of precision medicine by creating evidence and knowledge-based solutions that identify a patient’s susceptibility to disease, predict how the patient will respond to a particular drug, and match patients to the best therapies for an optimal treatment outcome. M2Gen, along with Moffitt and partnering community hospitals, has created a large, cancer-focused, biorepository linked to clinical and molecular data. For more information, visit www.m2gen.com.

About the Oncology Research Information Exchange (ORIEN)
Consisting of the nation’s leading cancer centers, the Oncology Research Information Exchange Network (ORIEN) is the world’s largest precision cancer research collaboration.  ORIEN utilizes a single protocol, Total Cancer Care®, to create a collaborative, “rapid learning” environment that will  share de-identified data to accelerate the development of targeted treatments, allowing researchers and clinicians to more quickly match eligible patients to clinical trials and conduct larger and richer analysis.The ORIEN collaborative continues to seek partnerships with other leading cancer centers in North America. More information may be found at ORIENcancer.org.

About Moffitt Cancer Center
Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the top-ranked cancer hospital in the Southeast and has been listed in U.S. News & World Report as one of the “Best Hospitals” for cancer care since 1999. With more than 4,500 employees, Moffitt has an economic impact in Florida of nearly $1.6 billion. For more information, visit MOFFITT.org, and follow the Moffitt momentum on FacebookTwitter and YouTube.

###